Hingten JN, Hendrie HC, Aprison MH (1984) Postsynaptic serotoninergic blockage following chronic antidepressive treatment with trazodone in an animal model of depression.
Henry JA, Ali CJ, Caldwell R (1984) Acute trazodone poisoning: clinical signs and plasma concentrations. Gershon S, Newton R (1980) Lack of anticholinergic side effects with a new antidepressant trazodone. Biol Psychiatry 9(2):117–123Ĭlements-Jewery S (1978) The development of cortical beta-adrenoreceptor subsensitivity in the rat by chronic treatment with trazodone, doxepin and mianserine. Psychopharmacology 84:1–4Ĭhernik DA, Mendels J (1974) Longitudinal study of the effects of lithium carbonate on the sleep of hospitalized depressed patients. Expertise du 21.1.83 unpublishedīrooks D, Prothero W, Bouras N (1984) Trazodone: a comparison of single night time and divided daily dosage regimens. Drugs 21(6):401–476īromet N: Etude de la biodisponibilité relative chez l'homme de comprimés et de soluté de trazodone. Psychopharmacology 55:121–128īrogden RN, Hell RC, Speight TM (1981–1984) Trazodone - a review of its pharmacological properties and therapeutic use in depression and anxiety. Nature 223:750–752īrezinova V, Adam K, Chapman K (1977) Viloxazine, sleep and subjective feelings. Br J Clin Pharmacol 11:505–509īaxter BL, Gluckman MI (1969) Iprindole: an antidepressant which does not block REM sleep.
These particularly valuable effects of trazodone on sleep would suggest that this drug should especially be given in cases of depression with major insomnia.Īnkier SI, Martin BK, Carpentier PK (1981) Trazodone: a new assay procedure and some pharmacokinetic parameters. In addition, records at the end of the study showed an increase in delta sleep and an increase in REM latency, an effect classically associated with an antidepressant action. From the beginning of treatment, there was a hypnotic-like effect (increase in total duration of sleep and stage II, decrease in sleep latency and intrasleep awakenings). Clinical improvement, as assessed by a reduction of more than 60% in MADRS scale scores, was accompanied by evidence of the definitely beneficial effects of trazodone on the disturbed sleep of these depressed patients. Weekly blood samples were collected to measure plasma levels of trazodone and, at the end of the study, the elimination half-life at steady state was calculated by repeated measurements of plasma levels. At the same time, the clinical evolution of patients was evaluated weekly using MADRS and Hamilton-Anxiety scales for anxiety-depression symptomatology and Spiegel and Norris sleep scales. The sleep parameters were compared to those obtained from three sleep recordings performed just prior to the initiation of the treatment and after 2 adaptation nights at the end of a 2-week drug-free period. The effects of 400–600 mg trazodone on the sleep patterns of ten depressed in-patients treated for 5 weeks were studied during the initial (days 1–3) and terminal (days 26–28) treatment periods.
0 kommentar(er)
